aging

First Opinion By Donald H. Taylor, Jr.

To test our way out of the Covid-19 nightmare, focus on nursing homes

Health By Shafaq Zia

As Covid-19 lockdowns are lifted, uncertainty at nursing homes only deepens

First Opinion By Jason Karlawish

Hospitalized adults need their caregivers — they aren’t visitors

First Opinion By Kali S. Thomas, Paula Carder, and David C. Grabowski

Assisted living and Covid-19: the next Kirkland might not be a nursing home

First Opinion By Attila Csordas

We need to take steps toward building a consensus definition of biological aging

Health Tech By Hiawatha Bray — Boston Globe

For homebound people and their distant caregivers, smarter speakers to keep track of their health

In the Lab By Sharon Begley

Our body systems age at different rates, study finds, pointing to personalized care to extend healthy life

First Opinion By Grace Hatton

Lost, and sometimes found, in the emergency department at Christmas

Don't Miss By Alissa Ambrose

‘You keep loving each other’: A window into dementia at the end of a lifelong partnership

Biotech By Rebecca Robbins

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

Biotech By Rebecca Robbins and Matthew Herper

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

In the Lab By Andrew Joseph

Scientists develop a ‘clock’ that can measure biological age based on blood proteins

Biotech By Rebecca Robbins

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

STAT Summit By STAT staff

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

Biotech By Adam Feuerstein, Rebecca Robbins, and Damian Garde

A medicinal chemist sees some red flags on China’s newly approved Alzheimer’s drug

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

Biotech By Damian Garde

With high stakes, eight experts would wield extraordinary influence on fate of Biogen’s Alzheimer’s drug

Health By Nicholas Florko

Bill Gates spends billions on global health. With Alzheimer’s, his science adviser says, money is not the issue

Health By Jonathan Saltzman — Boston Globe

Can a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?

Health By Robert Weisman — Boston Globe

Seniors clamor for high-dose flu shot, but it’s not always easy to find

Health By Damian Garde and Adam Feuerstein

An Alzheimer’s patient on what was lost when Biogen shut down its trial, and what may be gained again

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Every angle on Biogen’s shocking Alzheimer’s news

Pharmalot By Ed Silverman

Pharmalittle: States push back on opioid deal; sheriffs acted as front group to decry importation

In the Lab By Sharon Begley

7 burning questions now that Biogen has resurrected its ‘failed’ Alzheimer’s drug

Pharmalot By Ed Silverman

Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations